Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rax-CMC
- Development stage
- Unknown
- Lead developer
- Rax Health Care
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Rax-CMC is a topical ophthalmic lubricant developed and distributed by Rax Health Care Private Limited. The formulation contains 0.5% w/v sodium carboxymethylcellulose (carmellose), a high-viscosity polymer that functions as a tear substitute. It is indicated for the temporary relief of burning, irritation, and discomfort associated with dry eye syndrome. By mimicking the properties of natural tears, Rax-CMC helps maintain ocular surface lubrication and prevents rapid tear drainage, thereby protecting the eye from environmental irritants and maintaining moisture.
- Brand names
- Rax-CMC
- Other names
- sodium carboxymethylcellulose 0.5% eye dropscarmellose sodium 0.5% eye drops
Beyond the preview
Go deeper on Rax-CMC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rax-CMC.